甲巯咪唑联合雷公藤多苷片治疗甲亢的临床效果分析被引量：2

Clinical effect of methimazole combined with tripterygium glycosides tablets in the treatment of hyperthyroidism

下载PDF

导出

摘要目的:探讨甲巯咪唑联合雷公藤多苷片治疗甲亢的临床效果。方法:收治甲亢患者60例,随机分为对照组和观察组。对照组采用甲巯咪唑治疗,观察组采用甲巯咪唑联合雷公藤多苷片治疗。结果:观察组的AKP、BGP、GSH-Px、SOD、TSH、FT_4、FT_3和总有效率均优于对照组(P<0.05)。结论:甲巯咪唑联合雷公藤多苷片治疗甲亢的临床效果显著。 Objective:To explore the clinical effect of methimazole combined with tripterygium glycosides tablets in the treatment of hyperthyroidism.Methods:60patients with hyperthyroidism were selected.They were randomly divided into the control group and the observation group.The control group was treated with methimazole.The observation group was treated with methimazole combined with tripterygium glycosides tablet.Results:In the observation group,AKP,BGP,GSH-Px,SOD,TSH,FT4,FT3and total effective rate were better than those of the control group(P<0.05).Conclusion:The clinical effect of methimazole combined with tripterygium glycosides tablets in the treatment of hyperthyroidism was significant.

作者杜佳石丽 Du Jia;Shi Li(Shilipai Hospital of Yixing City 214200;The People's Hospital of Yixing City 214200)

机构地区宜兴市十里牌医院宜兴市人民医院

出处《中国社区医师》 2017年第25期34-34,36,共2页 Chinese Community Doctors

关键词甲巯咪唑雷公藤多苷片甲亢 Methimazole Tripterygium glycosides tablets Hyperthyroidism

分类号 R581.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献5

1敖文.他巴唑与强的松、雷公藤多甙联用治疗甲亢突眼征患者的疗效观察[J].中国民康医学,2015,27(13):95-96. 被引量：10
2张俊峰.甲巯咪唑联合雷公藤多苷治疗甲亢患者的疗效及安全性研究[J].中国社区医师,2015,31(21):67-67. 被引量：5
3裘佳音,朱燕,奚庆红.小剂量碘^(131)联合甲巯咪唑对甲亢患者甲状腺功能及血清CT、PTH、BGP的影响[J].海南医学院学报,2016,22(6):555-557. 被引量：58
4项旻,曾伟伟,叶成夫,黄贤恩.甲巯咪唑与丙基硫氧嘧啶对甲亢继发骨质疏松患者骨密度的影响[J].实用药物与临床,2014,17(11):1431-1434. 被引量：16
5龚敏,王爱华.硒酵母联合甲巯咪唑治疗Graves病合并甲亢的临床研究[J].中国中医药科技,2015,22(2):130-132. 被引量：21

二级参考文献58

1乔艺杰,王安宇,魏良纲.雷公藤多甙对Grave’s病甲状腺功能恢复的影响[J].贵州医药,2012,36(3):230-231. 被引量：4
2向大光.临床甲状腺病学[M].北京:人民卫生出版社,2013:108-193.
3Gorka J, Taylor-Gjevre RM, Arnason T. Metabolic and clinical consequences of hyperthyroidism on bone density [J]. Int J Endocrino1,2013 ,2013 :638727.
4Rosario PW. Radioiodine therapy in elderly patients with sub-clinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism [ J ]. Arq Bras Endocrinol Metabol,2013,57 (2) : 144-147.
5Wu X, Liu H, Zhu X, et al. Efficacy and safety of methimazole ointment for patients with hyperthyroidism[J]. Environ Toxi- col Pharmaco1,2013,36 ( 3 ) : 1109-1112.
6Feroci F, Rettori M, Borrelli A, et al. A systematic review and meta - analysis of total thyroidectomy versus bilateral subtotal thy- roidectomy for Graves" disease [ J ]. Surgery, 2014,155 ( 3 ) : 529 - 540.
7Hautzel H, Pisar E, Yazdan - Doust N, et al. Qualitative and quantitative impact of protective glucocorticoid therapy on the ef- fective 131I half- life in radioiodine therapy for Graves disease[ J] J Nucl Med,2010,51(12) :1917 -1922.
8Stefanic M, Kamer I. Thyroid peroxidase autoantibodies are asso- ciated with a lesser likelihood of late reversion to hyperthyroidism after successful nun - ablative treatment of Graves'disease in Croa- tian patients[J]. J Endocrinol Invest,2014,37( 1 ) :71 -77.
9Khong J J, Goldstein R F, Sanders K M, et al. Serum selenium status in Graves'disease with and without orbitopathy: a case - control study [ J ]. Clin Endocrinol (Oxf), 2014,80 ( 6 ): 905 -910.
10Bulow P I, Knudsen N, Carle A, et al. Serum selenium is low in newly diagnosed Graves" disease : a population - based study [ J ]. Clin Endocrinol (Oxf) ,2013,79(4) :584 -590.